Results 251 to 260 of about 195,829 (332)

The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study. [PDF]

J Parkinsons Dis, 2020
Huang X, Lewis MM, Van Scoy LJ, De Jesus S, Eslinger PJ, Arnold AC, Miller AJ, Fernandez-Mendoza J, Snyder B, Harrington W, Kong L, Wang X, Sun D, Delnomdedieu M, Duvvuri S, Mahoney SE, Gray DL, Mailman RB.   +17 more
europepmc   +1 more source

Cognitive enhancing effect of S-8510, a novel benzodiazepine partial inverse agonist, on event related potential (P300) in monkeys

, 1995
Kohji Abe, Masahito Horiuchi, Kohji Yoshimura   +2 more
openalex   +1 more source

Antagonistic effects of selective α1-adrenoceptor antagonists MDL73005EF and tamsulosin and partial agonists clonidine and tizanidine in rat thoracic aorta and rabbit iliac artery [PDF]

, 2001
Mitsutoshi Satoh, Keisuke Enomoto, Katsuo Koike   +2 more
openalex   +1 more source

Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment

Advanced Science, EarlyView.
This review summarizes recent advances in the spatiotemporal dynamics of the tumor microenvironment (TME). It highlights the roles of diverse immune and stromal cell populations, spatial architecture of the TME, as well as the gut and tumor microbiota in influencing responses to immune checkpoint inhibitors (ICIs), by integrating insights from single ...
Yuanyuan Zhang, Zhihua Liu
wiley   +1 more source

Electroencephalographic (EEG) properties of S-8510. a novel benzodiazepine partial inverse agonist, in rats

, 1995
Yukio Naito, Minoru Takeuchi, Tsuyoshi Kihara, Masato Ikeda, Nobuhiro Ibii, Akira Matsushita   +5 more
openalex   +1 more source

In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation

Advanced Science, EarlyView.
In this review, the basic concepts of in situ vaccination are discussed, its advantages over conventional vaccines, and key historical milestones, from the first use of Coley's toxins to the most recent FDA‐approved in situ vaccine for bladder cancer.
Yiru Shi, Yuxuan Hou, Moustafa T. Mabrouk, Chengzhong Yu, Yannan Yang   +4 more
wiley   +1 more source

Emerging cGAS‐STING Agonist‐Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy

Advanced Science, EarlyView.
This review summarizes recent advances in cGAS‐STING agonist‐based nanotherapeutics for cancer combination therapy. It explores nanoparticle‐mediated delivery strategies, underlying molecular mechanisms, and combinatorial applications with chemotherapy, radiotherapy, targeted therapy, phototherapy, sonodynamic therapy, and immunotherapy.
Zhaomeng Wang, Yongjun Wang, Zhonggui He, Caigang Liu   +3 more
wiley   +1 more source

Activation of single heteromeric GABA_A receptor ion channels by full and partial agonists [PDF]

, 2004
Martin Mortensen, Uffe Kristiansen, Bjarke Ebert, Bente Frølund, Povl Krogsgaard‐Larsen, Trevor G. Smart   +5 more
openalex   +1 more source

Inhaling Eugenol Inhibits NAFLD by Activating the Hepatic Ectopic Olfactory Receptor Olfr544 and Modulating the Gut Microbiota

Advanced Science, EarlyView.
Inhalable eugenol (EUG) from clove oil attenuates NAFLD by activating hepatic olfactory receptor Olfr544, triggering cAMP/PKA/CREB signaling to enhance lipolysis/oxidation. EUG concurrently restores gut microbiota, enriching probiotics (L. reuteri XR23/L. johnsonii XR25) and metabolites (IPA/5‐HIAA) that suppress lipogenesis.
Xiao‐Ran Wang, Zhan‐Zhan Li, Shu‐Ding Sun, Ya‐Gang Song, Jin‐Xin Miao, Xiang‐Xiang Wu, Yong‐Li Han, Xiao‐Lei Zhang, Wen‐Jing Chen, Qing‐Hua Wang, Yu Zhang, Yiping Fu, Yu‐ting Liu, Lin‐yan Lang, Wen‐Xia Zhao, Ming‐San Miao   +15 more
wiley   +1 more source

Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ. [PDF]

Biomolecules, 2020
Ahn S, Jang DM, Park SC, An S, Shin J, Han BW, Noh M.   +6 more
europepmc   +1 more source